

ASSEMBLY, No. 116

STATE OF NEW JERSEY

219th LEGISLATURE

PRE-FILED FOR INTRODUCTION IN THE 2020 SESSION

Sponsored by:

Assemblyman CHRISTOPHER P. DEPHILLIPS

District 40 (Bergen, Essex, Morris and Passaic)

Assemblyman KEVIN J. ROONEY

District 40 (Bergen, Essex, Morris and Passaic)

SYNOPSIS

Requires physician to offer to test patient for dihydropyrimidine dehydrogenase deficiency prior to patient undergoing chemotherapy.

CURRENT VERSION OF TEXT

Introduced Pending Technical Review by Legislative Counsel.



1 **AN ACT** concerning chemotherapy and supplementing Title 17B of
2 the New Jersey Statutes and Title 26 of the Revised Statutes.

3

4 **BE IT ENACTED** *by the Senate and General Assembly of the State*
5 *of New Jersey:*

6

7 1. a. A physician shall offer to test a patient for
8 dihydropyrimidine dehydrogenase deficiency prior to the patient
9 undergoing chemotherapy.

10 b. As used in this act, “dihydropyrimidine dehydrogenase
11 deficiency” means a disorder in which the human body experiences
12 difficulty or is unable to breakdown chemotherapy drugs leading to
13 a harmful reaction.

14

15 2. An individual health insurance policy that is delivered,
16 issued, executed, or renewed in this State pursuant to chapter 26 of
17 Title 17B of the New Jersey Statutes, or approved for issuance or
18 renewal in this State by the Commissioner of Banking and
19 Insurance, on or after the effective date of this act, shall provide
20 coverage for expenses incurred in conducting one test for
21 dihydropyrimidine dehydrogenase deficiency every year and any
22 prescription drug treatment of dihydropyrimidine dehydrogenase
23 deficiency, if the policy provides prescription drug benefits.

24 The benefits shall be provided to the same extent as for any other
25 condition under the policy.

26 This section shall apply to those policies in which the insurer has
27 reserved the right to change the premium.

28

29 3. A group health insurance policy that is delivered, issued,
30 executed, or renewed in this State pursuant to chapter 27 of Title
31 17B of the New Jersey Statutes, or approved for issuance or renewal
32 in this State by the Commissioner of Banking and Insurance, on or
33 after the effective date of this act, shall provide coverage for
34 expenses incurred in conducting one test for dihydropyrimidine
35 dehydrogenase deficiency every year and any prescription drug
36 treatment of dihydropyrimidine dehydrogenase deficiency, if the
37 policy provides prescription drug benefits.

38 The benefits shall be provided to the same extent as for any other
39 condition under the policy.

40 This section shall apply to those policies in which the insurer has
41 reserved the right to change the premium.

42

43 4. An individual health benefits plan that is delivered, issued,
44 executed, or renewed in this State pursuant to P.L.1992, c.161
45 (C.17B:27A-2 et seq.), or approved for issuance or renewal in this
46 State by the Commissioner of Banking and Insurance, on or after
47 the effective date of this act, shall provide coverage for expenses
48 incurred in conducting one test for dihydropyrimidine

1 dehydrogenase deficiency every year and any prescription drug
2 treatment of dihydropyrimidine dehydrogenase deficiency, if the
3 health benefits plan provides prescription drug benefits.

4 The benefits shall be provided to the same extent as for any other
5 condition under the health benefits plan.

6 This section shall apply to those health benefits plans in which
7 the carrier has reserved the right to change the premium.

8
9 5. A small employer health benefits plan that is delivered,
10 issued, executed, or renewed in this State pursuant to P.L.1992,
11 c.162 (C.17B:27A-17 et seq.), or approved for issuance or renewal
12 in this State by the Commissioner of Banking and Insurance, on or
13 after the effective date of this act, shall provide coverage for
14 expenses incurred in conducting one test for dihydropyrimidine
15 dehydrogenase deficiency every year and any prescription drug
16 treatment of dihydropyrimidine dehydrogenase deficiency, if the
17 health benefits plan provides prescription drug benefits.

18 The benefits shall be provided to the same extent as for any other
19 condition under the health benefits plan.

20 This section shall apply to those health benefits plans in which
21 the carrier has reserved the right to change the premium.

22
23 6. A health maintenance organization contract that is delivered,
24 issued, executed, or renewed in this State pursuant to P.L.1973,
25 c.337 (C.26:2J-1 et seq.), or approved for issuance or renewal in
26 this State by the Commissioner of Banking and Insurance, on or
27 after the effective date of this act, shall provide coverage for
28 expenses incurred in conducting one test for dihydropyrimidine
29 dehydrogenase deficiency every year and any prescription drug
30 treatment of dihydropyrimidine dehydrogenase deficiency, if the
31 health maintenance organization contract provides health care
32 services for prescription drugs.

33 The health care services shall be provided to the same extent as
34 for any other condition under the contract.

35 This section shall apply to those contracts for health care
36 services under which the right to change the schedule of charges for
37 enrollee coverage is reserved.

38
39 7. Pursuant to the "Administrative Procedure Act," P.L.1968,
40 c.410 (C.52:14B-1 et seq.), the Commissioner of Health, in
41 consultation with the State Board of Medical Examiners, shall pass
42 rules and regulations to effectuate the provisions of section 1 of this
43 act, and the Department of Banking and Insurance shall pass rules
44 and regulations to effectuate the provisions of sections 2 through 76
45 of this act.

46
47 8. This act shall take effect 90 days after the date of enactment.

STATEMENT

This bill requires a physician to offer to test a patient for dihydropyrimidine dehydrogenase deficiency prior to the patient undergoing chemotherapy. Dihydropyrimidine dehydrogenase deficiency is a disorder in which the human body experiences difficulty or is unable to breakdown chemotherapy drugs leading to a harmful reaction.

Under the bill, health insurance plans in this State are to cover expenses incurred in conducting one test for dihydropyrimidine dehydrogenase deficiency every year.